RUBY's Business Model
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://www.rubiustx.com |
| CEO (Chief Executive Officer) | Laurence A. Turka |
| Number of Employees | |
| IPO date | July 18, 2018 |
RUBY Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 399 Binney Street |
| City | Cambridge |
| State | MA |
| Phone | 617 679 9600 |
| Zip Code | 02139 |
| Other Identifiers | |
| CIK | 0001709401 |
| ISIN | US78116T1034 |
| CUSIP | 78116T103 |
| Open | 0.0555 |
| Previous Close | 0.0555 |
| Volume | 755.9 Thou. |
| Average Volume | 99.53 Thou. |
| Day’s Range | 0.055 – 0.057 |
| 52 Week Range | 0.0032-0.3763 |
| MA (50) | 0.021742 |
| MA (200) | 0.01987485 |
| Market Cap | 0 |
| Shares Out. | 0 |
| Earnings Date | Feb 26, 2024 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
